Physician profile
Nahomy Calixte
NPI 1033401625
$8,125.65
in general payments reported to CMS, 2019-2025
53 companies · $782 in 2025
The $782 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $465 · 2021: $787 · 2022: $2,092 · 2023: $892 · 2024: $1,543 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233 · Travel and Lodging: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.69 |
| Travel and Lodging | $984.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,636.13 | 2019-2025 | Ams 700 Cxr Rte Kit, Lithovue, Ams 700 |
| Teleflex LLC | $1,498.28 | 2021-2025 | Urolift, Barrigel |
| Uromedica, Incorporated | $825.32 | 2019 | |
| Astellas Pharma US INC | $449.10 | 2019-2024 | Xtandi |
| Myriad Genetic Laboratories, INC. | $326.13 | 2021-2025 | Myrisk, Prolaris |
| Axonics, INC. | $319.51 | 2020-2024 | Axonics |
| Endo Pharmaceuticals INC. | $315.15 | 2019-2024 | Xiaflex, Aveed, Edex |
| Coloplast Corp | $296.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $202.89 | 2020-2023 | Welireg, Keytruda, Lynparza |
| Pfizer INC. | $202.28 | 2019-2022 | |
| Caldera Medical, INC | $153.75 | 2023 | Desara |
| Ferring Pharmaceuticals INC. | $147.92 | 2024-2025 | Adstiladrin |
| Clarus Therapeutics INC. | $125.00 | 2021 | |
| Valencia Technologies Corporation | $110.31 | 2025 | Ecoin Device Kit |
| Pacira Pharmaceuticals Incorporated | $95.89 | 2019-2025 | Exparel |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nahomy Calixte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.